**Supplementary Figure legend**

**Supplementary Figure A1. The serum chemokine levels of DEB patients and controls**

The serum chemokine levels were measured by ELISAs: **(a)** HMGB1 (patients, n = 30; controls, n = 18); **(b)** CXCL12 (EB patients, n = 28; controls, n = 15); **(c)** CCL21 (EB patients, n = 30; controls, n = 19); **(d)** CCL19 (EB patients, n = 27; controls, n = 13); **(e)** CCL27 (EB patients, n = 29; controls, n = 19); **(f)** CCL28 (EB patients, n = 27; controls, n = 15)**.** Box plots show the distribution of chemokine levels in each group, and error bars are SEM. The statistical differences were determined by student’s t test. \*\**P* < 0.01, \*\*\*\**P* < 0.0001.

**Supplementary Figure B1. The serum chemokine levels of RDEB patients and affected BSA**

The affected BSA of RDEB patients were divided into four groups: 0-20%, 21-50%, 51-80%, 80% <. Data are expressed as the mean ± SEM. **(a)** HMGB1; **(b)** CXCL12; **(c)** CCL21; **(d)** CCL19; **(e)** CCL27; **(f)** CCL28 (RDEB patients, n = 21)**.**